Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
Open Access
- 24 June 2022
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 18 (6), e1010547
- https://doi.org/10.1371/journal.ppat.1010547
Abstract
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes. This article reviews the literature examining the inflammatory pathways resulting in pulmonary and cardiovascular adverse events associated with the Coronavirus Disease 2019 (COVID-19) and their role in the disease process; it also reviews the mechanism of action and safety profile of cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, previously studied in advanced clinical trials for treatment of HIV or nonalcoholic steatohepatitis (NASH), as a possible treatment option to prevent severe respiratory and cardiovascular outcomes in patients with COVID-19.Keywords
Funding Information
- AbbVie
This publication has 104 references indexed in Scilit:
- CCR2-Antagonist Prophylaxis Reduces Pulmonary Immune Pathology and Markedly Improves Survival during Influenza InfectionThe Journal of Immunology, 2011
- Upregulation of the Chemokine (C-C Motif) Ligand 2 via a Severe Acute Respiratory Syndrome Coronavirus Spike-ACE2 Signaling PathwayJournal of Virology, 2010
- Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+T Cells Are Important in Control of SARS-CoV InfectionJournal of Virology, 2010
- Chemokines in Vascular Dysfunction and RemodelingArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta‐Analysis of 4 Cohorts in the US EpidemicThe Journal of Infectious Diseases, 2008
- Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaquesJCI Insight, 2007
- Migratory fate and differentiation of blood monocyte subsetsImmunobiology, 2006
- CCR5 deficiency increases risk of symptomatic West Nile virus infectionThe Journal of Experimental Medicine, 2006
- TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in HumansAntimicrobial Agents and Chemotherapy, 2005
- The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary diseasePharmacology & Therapeutics, 2005